Brokerages expect Aileron Therapeutics (NASDAQ:ALRN) to report earnings per share (EPS) of ($0.51) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aileron Therapeutics’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.49). Aileron Therapeutics reported earnings per share of ($0.45) in the same quarter last year, which indicates a negative year-over-year growth rate of 13.3%. The business is scheduled to report its next quarterly earnings results on Thursday, August 9th.
On average, analysts expect that Aileron Therapeutics will report full-year earnings of ($2.06) per share for the current financial year, with EPS estimates ranging from ($2.24) to ($1.95). For the next fiscal year, analysts expect that the company will report earnings of ($2.20) per share, with EPS estimates ranging from ($2.26) to ($2.11). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Aileron Therapeutics.
Aileron Therapeutics (NASDAQ:ALRN) last released its earnings results on Wednesday, May 9th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.02).
Separately, ValuEngine upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Aileron Therapeutics has a consensus rating of “Buy” and a consensus price target of $19.33.
In other news, major shareholder Apple Tree Partners Ii Lp sold 107,904 shares of the stock in a transaction on Thursday, April 19th. The shares were sold at an average price of $6.31, for a total value of $680,874.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Several hedge funds have recently made changes to their positions in ALRN. Bank of New York Mellon Corp acquired a new position in shares of Aileron Therapeutics in the 3rd quarter valued at $135,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Aileron Therapeutics in the 3rd quarter worth about $165,000. California State Teachers Retirement System bought a new stake in shares of Aileron Therapeutics in the 3rd quarter worth about $110,000. Finally, Endurant Capital Management LP grew its holdings in shares of Aileron Therapeutics by 24.0% in the 4th quarter. Endurant Capital Management LP now owns 85,997 shares of the company’s stock worth $906,000 after purchasing an additional 16,647 shares during the last quarter. Institutional investors own 7.94% of the company’s stock.
Aileron Therapeutics opened at $5.45 on Friday, Marketbeat reports. Aileron Therapeutics has a one year low of $5.40 and a one year high of $5.61. The firm has a market cap of $80.32 million and a P/E ratio of -3.08.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.